期刊文献+

维持性血液透析患者矿物质与骨代谢紊乱影响因素分析 被引量:11

Correlation Factors with Mineral and Bone Disorder in Maintenance Hemodialysis Patients
暂未订购
导出
摘要 目的了解维持性血液透析(MHD)患者钙磷代谢情况及血清全段甲状旁腺素(iPTH)水平以评估矿物质与骨代谢紊乱(MBD)情况,并进行相关影响因素分析。方法采用横断面研究方法调查南华大学附属第二医院血液净化中心116例MHD患者矿物质与骨代谢指标达标情况,并分析其与年龄、性别、透析时间、体重指数(BMI)、血红蛋白(Hb)、肾功能、碱性磷酸酶(ALP)、高血压、糖尿病之间的相关性。结果 116例患者中,54例(46.55%)血清钙浓度、37例(31.90%)血磷浓度、71例(61.20%)钙磷乘积和36例(31.03%)iPTH达到指南要求;上述指标均达标者仅有19例(16.38%)。MBD与肾功能、Hb、BMI、高血压相关,与年龄、性别、透析时间不相关。高ALP与高水平iPTH相关,高血糖与低水平iPTH相关。结论多数MHD患者存在MBD,其发生与肾功能、血红蛋白水平、BMI、有无高血压密切相关。此外,升高的骨ALP与高iPTH可联合预测肾性骨病的类型。高血糖可能是MBD的易感因素。 Objective To understand the controlling situation of mineral and bone disorder(MBD) in maintenance hemodialysis patients,and analyze their related factors.Methods We investigated MBD in 116 maintenance hemodialysis patients in Hemodialysis Center of the Second Affiliated Hospital of NanHua University,and compared these data with the guidelines.We also analyzed age,gender,years for dialysis,body mass index(BMI),Hb,renal function,alkaline phosphatase(ALP),blood pressure,and diabetes mellitus in these patients.Results In the 116 cases,54(46.55%) cases of serum Ca,37(31.9%)cases of phosphate,71(61.20%)cases Ca×P product and 36(31.03%)cases of iPTH meet the requirements of the guidelines.However,normal values of the above 4 parameters recommended by KDIGO were only found in 19(16.38%)cases.Single variable regression analyses showed that MBD did not correlate with gender,age,and years for dialysis.However,worse renal function,lower Hb,lower BMI,and blood pressure were correlate with mineral and bone disorder.In addition,Higher level of ALP was correlate with higher iPTH level.But diabetic hemodialysis patients in lower iPTH-level group were more than other groups.Conclusion The control of the MBD could not conform to the standards in the KDIGO guidelines in most hemodialytic patients.The presence of MBD was associated with worse renal function,lower Hb and hypertension.Simultaneous measurement of serum iPTH and ALP levels may be the reliable tool to predict the type of MBD.High blood sugar level might be risk factor of MBD.
出处 《中南医学科学杂志》 CAS 2013年第3期267-269,272,共4页 Medical Science Journal of Central South China
关键词 维持性血液透析 矿物质与骨代谢紊乱 甲状旁腺激素 maintenance hemodialysis mineral and bone disorder parathyroid hormone
  • 相关文献

参考文献9

  • 1Eddington H, Kalra PA. The association of chronic kidney disease-mineral bone disorder and cardiovascular risk [ J]. J Ren Care,2010,36( Suppl I) :61-67.
  • 2Kidney Disease:Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guide- line for the diagnosis, evaluation, prevention, and treat- ment of chronic kidney disease-mineral and bone disorder (CKD-MBD) [ J]. Kidney Int, 2009,76 ( Suppl 113 ) : 1-130.
  • 3张岩,顾洒洒,吴淑燕.慢性肾脏病-矿物质和骨代谢异常的研究进展[J].中国骨质疏松杂志,2011,17(7):640-642. 被引量:2
  • 4Drechsler C, Grootendorst DC, Boeschoten EW, et al. Changes in parathyroid hormone, body mass index and the association with mortality in dialysis patients[ J]. Nephrol Dial Transplant ,2011,26 (4) : 1340-1346.
  • 5Snijder MB, van Dam RM, Visser M, et al. Adiposity in relation to vitamin D stat-us and parathyroid hormone lev-els: a population-based study in older men and women [ J ]. J Clin Endocrinol Metab, 2005,90 (7) :4119-4123.
  • 6de Mutsert R, Grootendorst DC, Boeschoten EW, et al. Subjective global assessent of nutritional status is strongly associated with mortality in chronic dialysis patients [ J ]. Am J Clin Nutr,2009,89(3):787-793.
  • 7Souberbielle JC, Cavalier E, Jean G. Interpretation of ser- um parathyroid hormone concentrations in dialysis pa- tients:what do the KDIGO guidelines change for the clin- ical laboratory [ J ]. Clin Chem Lab Med, 2010,48 ( 6 ) : 769-774.
  • 8Okuno S. Kidney and bone update:the 5-year history and future of CKD-MBD. Bone metabolic marker in hemodial- ysis patients update [ J ]. Clin Calcium, 2012,22 ( 7 ) : 1009-1017.
  • 9易扬,路建饶,郭志勇.血液透析患者低转化性肾性骨病的治疗研究进展[J].中国中西医结合肾病杂志,2012,13(5):465-467. 被引量:12

二级参考文献49

  • 1王汉民,于艳.肾性骨病药物治疗进展[J].世界临床药物,2006,27(2):86-89. 被引量:6
  • 2顾波,路建饶.尿毒症中高磷和心血管钙化研究新进展[J].国际泌尿系统杂志,2006,26(4):566-568. 被引量:5
  • 3Eddington H, Kalra PA. The association of chronic kidney disease-mineral bone disorder and cardiovascular risk. J Ren Care, 2010, 36 ( Suppl 1 ) :61-67.
  • 4Matuszkiewicz-Rowi~ska J. KDIGO clinical practice guidelines for the diagnosis, evaluation, prevention, and treatment ofmineral and bone disorders in chronic kidney disease. Pol Arch Med Wewn, 2010, 120(7-8) :300-306.
  • 5Moe SM, Drueke T. Improving global outcomes in mineral and bone disorders. Clin J Am Soe Nephrol,2008,3 ( Suppl 3 ) : 127- 130.
  • 6Souqiyyeh MZ, Shaheen FA. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidneydisease-mineral and bone disorder (CKD-MBD). Saudi Kidney Dis Tranapl, 2010, 21(1) :93-101.
  • 7Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patientswith chronic kidney disease : results of the study to evaluate early kidney disease. Kidney Int, 2007, 71 ( 1 ) :31-38.
  • 8Almaden Y, Felsenfeld A J, Rodfiguez M, et al. Proliferation in hyperplastie human and normal rat parathyroid glands: role ofphosphate, calcitriol, and gender. Kidney Int, 2003, 64 (6): 2311-2317.
  • 9Kestenbaum B, Sampson JN, Rudser KD, et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soe Nephrol, 2005, 16(2) :520-528.
  • 10Toussaint ND, Elder GJ, Kerr PG. Bisphosphonates in chronic kidney disease ; balancing potential benefits and adverse effects on hone and soft tissue. Clin J Am Soc Nephrol, 2009, 4 ( 1 ) : 221-233.

共引文献12

同被引文献107

引证文献11

二级引证文献80

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部